Ces Urol X:X | DOI: 10.48095/cccu2026021
Major statement: Intravenous administration normal saline (0.9% sodium chloride solution) during CT excretory urography does not lead to a demonstrable improvement in filling or opacification of the upper urinary tract, and its routine use is not justified.SummaryAim: The aim of this study was to retrospectively evaluate whether intravenous administration of normal saline 0.9% sodium chloride solution (0.9% NaCl) during CT excretory urography improves filling and opacification of the upper urinary tract.
Material and methods: A cohort of patients referred for CT excretory urography between January and June 2025 was analysed. The standard CT protocol consisted of non-enhanced, arterial, parenchymal and excretory phases. During the examination, 90 mL of contrast agent and 50 mL of 0.9% NaCl were administered using a power injector. In half of the patients, an intravenous infusion of 120 mL of 0.9% NaCl was administered between parenchymal and excretory phase, while the remaining patients did not receive 0.9% NaCl infusion. The ureters were bilaterally divided into four segments, and contrast opacification of each segment was assessed on a four-point scale by two independent radiologists. In addition, renal pelvis density and intra-renal anteroposterior diameter were measured, as well as diameter and density of abdominal portion of the ureterall assessed bilaterally.
Results: Very good interobserver agreement was demonstrated for all quantitative and ordinal parameters (intraclass correlation coefficient – ICC > 0.9; Cohen\'s κ = 0.556–0.837). No statistically significant differences were found between patients with and without intravenous 0.9% NaCl administration for any of the evaluated parameters (all P > 0.05).
Conclusion: Intravenous 0.9% NaCl administration during CT excretory urography did not result in a statistically significant improvement in urinary tract filling or opacification compared with patients who did not receive 0.9% NaCl infusion.
Received: June 26, 2026; Revised: August 6, 2026; Accepted: August 26, 2026; Prepublished online: November 3, 2026
Go to original source...
Go to original source...
Go to PubMed...
Go to original source...
Go to PubMed...
Go to original source...
Go to original source...
Go to original source...
Go to original source...
Go to PubMed...
Go to original source...
Go to PubMed...